New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 9, 2014
07:46 EDTKPTIKaryopharm announces initiation of Selinexor Phase 2 study
Karyopharm Therapeutics announced the initiation of a Phase 2 trial of its novel, oral Selective Inhibitor of Nuclear Export compound Selinexor, or KPT-330, in patients with metastatic hormone-refractory prostate cancer. The study, referred to as the SHIP, or Selinexor in Hormone Refractory Indications in Prostate Cancer, study, is led by Drs. Christopher Logothetis and John Araujo of the M.D. Anderson Cancer Center at the University of Texas in Houston and is being funded in part by a grant from the Prostate Cancer Foundation.
News For KPTI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 29, 2015
12:39 EDTKPTIFly Watch: Several names that may move following ASCO meeting
Subscribe for More Information
07:06 EDTKPTIAmerican Society of Clinical Oncology to hold annual meeting
Subscribe for More Information
May 28, 2015
08:12 EDTKPTIKaryopharm initiates STORM clinical trial of KPT-330 in multiple myeloma
Subscribe for More Information
May 19, 2015
08:57 EDTKPTILeerink biotech analyst holds an analyst/industry conference call
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use